Should You Take It
Prsentation: Stechampulle | 5 ml | 0,176 fl
The trial enrolled 281 participants across 42 research and healthcare centers in the United States, randomized to once-weekly subcutaneous retatrutide (0.5, 4, 8, or 12 mg), once-weekly subcutaneous dulaglutide 1.5 mg (active comparator), or placebo, over a 36-week treatment period
Its history began with a breakthrough by a research team at the University of Texas, USA, in 2017.At that time, NNMT was recognized as a key enzyme in cellular metabolism and energy homeostasis, highly active in adipose tissue and closely linked to obesity, type 2 diabetes, and other metabolic diseases
This review seeks to consolidate ferroptosis studies in OA, providing insights into the targeting of its critical elements for innovative OA therapies